Inovio Pharmaceuticals (FRA:GBM) LT-Debt-to-Total-Asset : 0.09 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Inovio Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Inovio Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.09.

Inovio Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2023 (0.05) to Mar. 2024 (0.09). It may suggest that Inovio Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Inovio Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Inovio Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals LT-Debt-to-Total-Asset Chart

Inovio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.68

0.07

0.06

0.08

0.07

Inovio Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.05	0.06	0.07	0.09

Inovio Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Inovio Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	10.116	/	156.762
	=	0.06

Inovio Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	10.369	/	118.785
	=

Inovio Pharmaceuticals (FRA:GBM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Inovio Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals (FRA:GBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (FRA:GBM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

INO:USA INO:Mexico

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals (FRA:GBM) Headlines

No Headlines